The PLAJEX™ 2.25 mL with Tapered Needle* is specifically designed to meet the Biotech market, making it suitable for complex drug applications, such as high viscosity biotech medications.
The syringe enables pharmaceutical customers to offer a safe, easy-to-use, and effective treatment option that maximizes patient convenience.
Yuki Takeuchi, Global Product Manager for PLAJEX™ platform, said that the syringes are designed to address the unmet needs of biotech companies that are dealing with challenging and highly viscous biologic drugs, such as highly concentrated monoclonal antibodies.
He said: "With the rise of biologic formulations, and the increasing trend in self-administration, a drug delivery device needs to be easy-to-use, be able to deliver drugs safely, comfortably with suitable force. Our latest offering with Tapered Needle technology addresses the challenge of delivering highly viscous drugs without compromising patient comfort."
"Some biologic drugs are less stable in a liquid formulation, therefore PLAJEX™ syringe is designed as silicone oil-free which contributes to keeping sensitive drugs stable."
As the latest addition to the PLAJEX™ range, these primary container solutions come sterilized, and ready for filling, offering silicone oil-free, tungsten-free and glue-free containers made with precise polymer molding technology to provide tight dimensional tolerances.
Terumo's proprietary i-coating™ stopper technology eliminates the need of silicone oil in the syringe system while providing consistent and predictable break-loose and glide forces.
The PLAJEX 2.25 mL with Tapered Needle is compatible with some of marketed injection devices, while additional compatibility studies are ongoing with leading device providers.
Terumo Pharmaceutical Solutions will help customer's smooth fill & finish integration either by offering Terumo's in-house CDMO (Contract Development and Manufacturing Organization) capability, or supporting drug filling sites selected by customer.
Anil Busimi, VP Strategy & Marketing, added: "Terumo is in a unique position being able to offer an integrated solution of primary container and fill & finish capability. We continue to expand our portfolio with innovative injectable drug delivery solutions to meet pharma customers and patient's needs."
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.